Aligos Therapeutics Statistics Share Statistics Aligos Therapeutics has 6.15M
shares outstanding. The number of shares has increased by -0.81%
in one year.
Shares Outstanding 6.15M Shares Change (YoY) -0.81% Shares Change (QoQ) 0.01% Owned by Institutions (%) 38.14% Shares Floating 4.88M Failed to Deliver (FTD) Shares 5 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 391.88K, so 6.41% of the outstanding
shares have been sold short.
Short Interest 391.88K Short % of Shares Out 6.41% Short % of Float 7.53% Short Ratio (days to cover) 4.3
Valuation Ratios The PE ratio is -1.9 and the forward
PE ratio is -0.85.
Aligos Therapeutics's PEG ratio is
0.
PE Ratio -1.9 Forward PE -0.85 PS Ratio 63.27 Forward PS 16.2 PB Ratio -8.61 P/FCF Ratio -3.09 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Aligos Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.86,
with a Debt / Equity ratio of -0.29.
Current Ratio 2.86 Quick Ratio 2.86 Debt / Equity -0.29 Debt / EBITDA -0.09 Debt / FCF -0.1 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $56.36K Profits Per Employee $-1.87M Employee Count 70 Asset Turnover 0.06 Inventory Turnover n/a
Taxes Income Tax 331K Effective Tax Rate -0.25%
Stock Price Statistics The stock price has increased by -45.02% in the
last 52 weeks. The beta is 2.77, so Aligos Therapeutics's
price volatility has been higher than the market average.
Beta 2.77 52-Week Price Change -45.02% 50-Day Moving Average 7.77 200-Day Moving Average 15.24 Relative Strength Index (RSI) 45.45 Average Volume (20 Days) 114,927
Income Statement In the last 12 months, Aligos Therapeutics had revenue of 3.94M
and earned -131.21M
in profits. Earnings per share was -20.94.
Revenue 3.94M Gross Profit 3.94M Operating Income -89.15M Net Income -131.21M EBITDA -89.15M EBIT -89.15M Earnings Per Share (EPS) -20.94
Full Income Statement Balance Sheet The company has 37M in cash and 8.38M in
debt, giving a net cash position of 28.62M.
Cash & Cash Equivalents 37M Total Debt 8.38M Net Cash 28.62M Retained Earnings -618.01M Total Assets 134.71M Working Capital 107.68M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -80.74M
and capital expenditures -130K, giving a free cash flow of -80.87M.
Operating Cash Flow -80.74M Capital Expenditures -130K Free Cash Flow -80.87M FCF Per Share -12.91
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -2259.92% and -3326.01%.
Gross Margin 100% Operating Margin -2259.92% Pretax Margin -3317.62% Profit Margin -3326.01% EBITDA Margin -2259.92% EBIT Margin -2259.92% FCF Margin -2050.01%
Dividends & Yields ALGS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ALGS is $70,
which is 839.6% higher than the current price. The consensus rating is "Buy".
Price Target $70 Price Target Difference 839.6% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 19, 2024. It was a
backward
split with a ratio of 1:25.
Last Split Date Aug 19, 2024 Split Type backward Split Ratio 1:25
Scores Altman Z-Score -6.15 Piotroski F-Score 2
